Urgent Needs in Cancer



VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures. In preclinical studies, we have observed that the removal of CD33 provided robust protection of these healthy donor HSCs from the cytotoxic effects of CD33-directed companion therapeutics yet had no deleterious effects on the differentiation or function of hematopoietic cells.

Vor is initiating VBP101, a Phase 1/2 clinical trial in patients with CD33-positive acute myeloid leukemia (AML) who are at high risk of relapse. The primary goals of the trial are to evaluate tolerability and feasibility of the VOR33 stem cell transplant, with a focus on confirming that VOR33 can engraft normally. Following engraftment, patients will be eligible to be treated with Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy, in order to potentially prolong leukemia-free survival and provide evidence that VOR33 protects against the myelosuppression that typically accompanies treatment with Mylotarg.

Read more about our VBP101 clinical trial.

Licensed from the National Institutes of Health, VCAR33 is a CD33-directed chimeric antigen receptor T cell (CAR-T) therapy. A T cell therapy using the same CAR construct as VCAR33 is being studied in a multi-site Phase 1/2 clinical trial as an autologous monotherapy bridge-to-transplant for relapsed and/or refractory AML patients, sponsored by the National Marrow Donor Program (NMDP).

*A T cell therapy using the same CAR construct as VCAR33 is being studied in a Phase 1/2 clinical trial sponsored by the NMDP, and timing of data release is dependent on the investigators conducting the trial. We expect to either assume sponsorship and oversight of the NMDP trial prior to its completion or enter into an agreement with the NMDP providing us with the right to cross-reference the trial results in future IND applications that we may submit to the FDA, however, there is no assurance that we will be successful in these endeavors. We believe the T cell therapy being evaluated in the NMDP trial is comparable to VCAR33 and that the trial, if successful, will support future clinical development of VCAR33. However, the FDA may reject our claim of comparability or the sufficiency of the data to support it or disagree with our ability to reference the data generated by NMDP. If any of foregoing were to occur, we will be required to repeat certain development steps, which would involve us conducting additional IND-enabling studies as depicted in the graphic above. See “Risk Factors – We have not successfully tested our product candidates in clinical trials and any favorable preclinical results are not predictive of results that may be observed in clinical trials.”

We believe VOR33 and VCAR33 could be highly synergistic as a Treatment System, potentially enabling prolonged remissions or cures in the post-transplant setting. We intend to investigate the VOR33/VCAR33 Treatment System, entailing VOR33 eHSC therapy followed by VCAR33 as a companion therapeutic, initially for transplant-eligible patients suffering from AML. We believe VCAR33 could be a potent anticancer therapy that, when combined with VOR33, could help obviate severe on-target myeloablative toxicities and unlock the efficacy potential of VCAR33. In addition, in this setting, VCAR33 T cells could be sourced from the same cell source as VOR33 (allogeneic cells), which may provide benefits such as a healthier, more abundant cell source alongside lower risk of host T cells attacking CAR-T cells, thereby potentially prolonging persistence. If our anticipated trials for the VOR33/VCAR33 Treatment System are successful, we will have the potential to provide a single-company solution for patients suffering from certain hematological malignancies.

  • Leveraging our proprietary Vor platform, we have identified additional surface targets such as CD123 and CLL-1 as well as multiplex genome engineering approaches where multiple surface targets are removed.
  • Additionally, we are conducting ongoing discovery efforts on undisclosed targets for non-myeloid malignancies.

AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is characterized by excessive proliferation of myeloid stem cells and their failure to properly differentiate into mature blood cells.1 There are an estimated 42,500 new diagnoses of AML each year in the United States, Europe and Japan.2, 3 The average five-year survival rate for patients with AML is less than 30%,4 but there are significant differences in prognosis depending on several factors, including the age of the patient at diagnosis.

For many of these patients, the only way to achieve durable remission or a cure is through hematopoietic stem cell transplant (HSCT), a procedure in which stem cells are obtained from matched healthy donors and administered following myeloablation to patients, resulting in reconstitution of the patient’s hematopoietic system with donor-derived cells. Over the past 20 years, there has been an increasing trend in allogeneic transplants for AML. There were over 16,000 allogeneic HSCT procedures performed in the United States between 2013 and 2017 for the treatment of AML. Despite this, approximately 40 percent of AML patients relapse within two years of their transplant and face an extremely poor prognosis, with two-year survival rates of less than 20%. Though targeted therapies are an effective treatment for many patients in transplant settings who relapse, these therapies are limited by toxicities resulting from the expression of the surface targets on healthy cells, including these new transplanted cells, which is referred to as on-target toxicity.

CD33 is an attractive target for the development of AML therapeutics based on preclinical and clinical results from third parties demonstrating the ability of anti-CD33 directed therapies to deplete tumor cells. However, CD33-directed therapeutic approaches have had limited impact in improving the prognosis of patients with AML due in part to on-target toxicity.

1. Leukemia – Acute Myeloid – AML: Statistics. Available at: https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics#:~:text=AML%20is%20the%20second%20most,of%20diagnosis%20is%20age%2068.
2. Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML). Available at: https://seer.cancer.gov/statfacts/html/amyl.html
3. O. Visser. Incidence, survival and prevalence of myeloid malignancies in Europe. EJC. Avaliable at: https://www.ejcancer.com/article/S0959-8049(12)00469-8/fulltext
4. Acute Myeloid Leukemia (AML) SEER Survival Rates by Time Since Diagnosis, 2000-2016. Available at: https://seer.cancer.gov/explorer/application.html?site=96&data_type=4&graph_type=6&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_display=2